Seven Clinical Trial Read-Outs Due In Q4

The last three months of the year should see data reporting from a number of key studies for novel products including Roche's emicizumab. Scrip takes a look at some of the more interesting studies expected by year end, with the help of analysts from Informa's Biomedtracker.